Pomerantz Law Firm Launches Investigation into ADC Therapeutics for Investors' Claims

In the midst of unsettling news for investors, the Pomerantz Law Firm has announced its investigation into ADC Therapeutics SA (NYSE: ADCT) concerning allegations of possible securities fraud and unlawful business practices. On December 3, 2025, the company disclosed updates regarding its clinical trial data, which has raised significant concerns among stakeholders.

In the press release issued by ADC Therapeutics, the company revealed updated results from the ongoing LOTIS-7 Phase 1b clinical trial that assesses the safety and efficacy of ZYNLONTA® in combination with glofitamab in patients suffering from relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL). While the announcement contained optimistic language concerning the trial’s outcomes, it also underscored that adverse events were noted in two participants. Unfortunately, one of these occurrences appeared to be related to the treatment itself, casting doubts on the overall safety profile of the drug.

Worse still, the release highlighted that a significant percentage of trial participants—36.7%—experienced cytokine release syndrome, a severe reaction to certain therapies. This information sparked concern and trepidation, inevitably impacting ADC's stock price. Following the release of this data, the company saw a notable decline in its stock value, which plunged by 14.13%, closing at $3.95 per share that day.

The investigation by Pomerantz is seeking to determine whether the company’s leadership, including its officers and directors, have engaged in deceptive practices that may have exposed investors to undue risks. This inquiry follows the firm's long-standing commitment to protect the rights of investors who have endured losses due to corporate misconduct.

Pomerantz LLP, renowned for its expertise in securities class litigation, has been championing the rights of investors for over 85 years. Founded by the late Abraham L. Pomerantz, who is acknowledged as a pioneer in the class action sector, the firm has a proven track record of recovering substantial damages for victims of securities fraud and breaches of fiduciary duty. They offer a platform for affected investors to unite and potentially recover their losses through collective legal action, which is often more effective than pursuing individual claims.

Investors feeling the impact of ADC's recent trial updates are encouraged to reach out to Danielle Peyton of Pomerantz LLP for further details about joining the investigation. Potential participants can contact her via email or phone to voice their concerns and explore their options for involvement in this inquiry.

Individuals are reminded that regulatory authorities emphasize the importance of transparency and ethics in biotechnology companies, particularly those listed on major exchanges like the NYSE. As ADC Therapeutics navigates this challenging landscape, affected shareholders are advised to remain vigilant and proactive in seeking recourse for their investments.

As the investigation unfolds, further developments are anticipated, which may provide greater clarity on the situation surrounding ADC Therapeutics and its business practices, as well as the efficacy of the treatments it is developing. Investors should keep an eye on announcements from both ADC and Pomerantz as this story continues to evolve. Each step taken in this legal journey could not only affect the future of ADC but also serve as a bellwether for investor rights and corporate governance in the biotech industry.